Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol

被引:1
|
作者
Gastens, Viktoria [1 ,2 ]
Del Giovane, Cinzia [1 ,3 ]
Anker, Daniela [1 ,3 ]
Feller, Martin [1 ,4 ]
Syrogiannouli, Lamprini [1 ]
Schwab, Nathalie [1 ,4 ]
Bauer, Douglas C. [5 ,6 ]
Rodondi, Nicolas [1 ,4 ]
Chiolero, Arnaud [7 ]
机构
[1] Univ Bern, Inst Primary Hlth Care BIHAM, Bern, Switzerland
[2] Univ Bern, Grad Sch Hlth Sci, Bern, Switzerland
[3] Univ Fribourg, Populat Hlth Lab, PopHealthLab, Fribourg, Switzerland
[4] Univ Bern, Univ Hosp Bern, Inselspital, Dept Gen Internal Med, Bern, Switzerland
[5] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[6] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[7] McGill Univ, Sch Global & Populat Hlth, Montreal, PQ, Canada
来源
BMJ OPEN | 2021年 / 11卷 / 08期
基金
瑞士国家科学基金会;
关键词
preventive medicine; public health; statistics & research methods; MODEL; MORTALITY; IMPACT;
D O I
10.1136/bmjopen-2020-048168
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Older multimorbid adults have a high risk of mortality and a short life expectancy (LE). Providing high-value care and avoiding care overuse, including of preventive care, is a serious challenge among multimorbid patients. While guidelines recommend to tailor preventive care according to the estimated LE, there is no tool to estimate LE in this specific population. Our objective is therefore to develop an LE estimator for older multimorbid adults by transforming a mortality prognostic index, which will be developed and internally validated in a prospective cohort. Methods and analysis We will analyse data of the Optimising Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older People cohort study in Bern, Switzerland. 822 participants were included at hospitalisation with age of 70 years or older, multimorbidity (three or more chronic medical conditions) and polypharmacy (use of five drugs or more for >30 days). All-cause mortality will be assessed during 3 years of follow-up. We will apply a flexible parametric survival model with backward stepwise selection to identify the mortality risk predictors. The model will be internally validated using bootstrapping techniques. We will derive a point-based risk score from the regression coefficients. We will transform the 3-year mortality prognostic index into an LE estimator using the Gompertz survival function. We will perform a qualitative assessment of the clinical usability of the LE estimator and its application. We will conduct the development and validation of the mortality prognostic index following the Prognosis Research Strategy (PROGRESS) framework and report it following the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement. Ethics and dissemination Written informed consent by patients themselves or, in the case of cognitive impairment, by a legal representative, was required before enrolment. The local ethics committee (Kantonale Ethikkommission Bern) has approved the study. We plan to publish the results in peer-reviewed journals and present them at national and international conferences.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Development and internal validation of a new life expectancy estimator for multimorbid older adults
    Gastens, V.
    Chiolero, A.
    Anker, D.
    Feller, M.
    Bauer, D.
    Rodondi, N.
    Del Giovane, C.
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2022, 32
  • [2] Development and Validation of the Life Expectancy Estimator for Older Adults with Diabetes (LEAD): the Diabetes and Aging Study
    Andrew J. Karter
    Melissa M. Parker
    Howard H. Moffet
    Kasia J. Lipska
    Neda Laiteerapong
    Richard W. Grant
    Catherine Lee
    Elbert S. Huang
    [J]. Journal of General Internal Medicine, 2023, 38 : 2860 - 2869
  • [3] Development and Validation of the Life Expectancy Estimator for Older Adults with Diabetes (LEAD): the Diabetes and Aging Study
    Karter, Andrew J. J.
    Parker, Melissa M. M.
    Moffet, Howard H. H.
    Lipska, Kasia J. J.
    Laiteerapong, Neda
    Grant, Richard W. W.
    Lee, Catherine
    Huang, Elbert S. S.
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2023, 38 (13) : 2860 - 2869
  • [4] Life expectancy in multimorbid older adults: Why it matters for preventive care
    Gastens, V.
    Chiolero, A.
    Anker, D.
    Feller, M.
    Bauer, D. C.
    Rodondi, N.
    Del Giovane, C.
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2022, 32
  • [5] Estimating life expectancy among older multimorbid adults to personalize preventive care
    Gastens, V.
    Del Giovane, C.
    Anker, D.
    Syrogiannouli, L.
    Schwab, N.
    Rodondi, N.
    Chiolero, A.
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2020, 30
  • [6] Polypharmacy in multimorbid older adults: protocol for a systematic review
    Sirois, Caroline
    Laroche, Marie-Laure
    Guenette, Line
    Kroger, Edeltraut
    Cooper, Dan
    Emond, Valerie
    [J]. SYSTEMATIC REVIEWS, 2017, 6
  • [7] Polypharmacy in multimorbid older adults: protocol for a systematic review
    Caroline Sirois
    Marie-Laure Laroche
    Line Guénette
    Edeltraut Kröger
    Dan Cooper
    Valérie Émond
    [J]. Systematic Reviews, 6
  • [8] Development and validation of a novel measure of resilience in older adults: a longitudinal cohort study
    Wu, Chenkai
    Li, Ya-Xi
    Marron, Megan M.
    Odden, Michelle C.
    Newman, Anne B.
    Sanders, Jason L.
    [J]. LANCET, 2019, 394 : 10 - 10
  • [9] Life expectancy and active life expectancy by disability status in older US adults
    Jia, Haomiao
    Lubetkin, Erica, I
    [J]. PLOS ONE, 2020, 15 (09):
  • [10] Life expectancy among older adults with or without frailty in China: multistate modelling of a national longitudinal cohort study
    Gao, Junling
    Wang, Yujie
    Xu, Jixiang
    Jiang, Junjia
    Yang, Shitong
    Xiao, Qianyi
    [J]. BMC MEDICINE, 2023, 21 (01)